
Dicella sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Dicella develops an integrated clinical trial platform for sponsors, CROs, and research teams, bringing together eCRF, eTMF, CTMS, IWRS, patient diaries, and study operations. It also offers AI-assisted configuration and blockchain-based data integrity features, supporting teams throughout the clinical trial process.
Financials
Revenue history (in k)
From the notes
| Profit allocation | Retained in reserve capital | |
| Loans and borrowings | $376,526 | |
| Capital expenditure | $206,911 | |
| Foreign sales | 32.68% of revenue ($73,965) | |
| Revenue structure | Sprzedaż usług | |
| R&D costs | $131,431 |
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 255 days for 2021).
- 202522/07/2026
- 202418/08/2025
- 202320/06/2024
- 202231/12/2023
- 202127/03/2023
- 202030/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Clinical trial software
- Electronic trial master file system
- Clinical data capture system
- Clinical trial management system
- Clinical trial randomization system
- Patient diary
- Diagnostic imaging analytics
Websites
- dicella.comUnified clinical trial platform for reliable eTMF, eCRF, CTMS and study operations | diCELLaGoogle AnalyticsGoogle Tag ManagerNginx
Public procurement
4 tenders recorded as contractor: 3 national ($135,034) and 1 EU ($237,894).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| May 26, 2026 | Purchase, delivery and implementation of a clinical trial management system (CTMS) and purchase of additional licences for the amms system, including implementation. | $118.9K$118,947 | Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie | |
| May 21, 2026 | Purchase, delivery and implementation of a clinical trial management system (CTMS) and purchase of additional licences for the amms system, including implementation. | $118.9K$118,947 | Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie | |
| Jul 21, 2025 | Delivery, implementation and warranty servicing of an electronic patient diary creator (EDP creator) for remote data collection in a clinical trial. | $36,628$36,628 | Uniwersytet Medyczny w Łodzi |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the joint action of two members of the management board, or one member of the management board jointly with a commercial proxy, is required to submit declarations of will concerning the rights and obligations.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Aleksandra Kubica-Misztal age 40 | 950 | $12,830.90 | 39.0625% |
Krzysztof Paweł Misztal age 41 | 950 | $12,830.90 | 39.0625% |
| 532 | $7,185.31 | 21.875% |
Aleksandra Kubica Misztal and Krzysztof Paweł Misztal hold a combined 78.1% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-01-05.
97 1240 1444 1111 0010 7712 9797
44 1240 1444 1111 0010 7713 0751
19 1240 4432 1111 0010 8760 8185
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 11, 2019 | Call to creditors |
Public aid
32 public aid cases recorded, with a total value of $1,186,162.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 11, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $27,727$27,727 | Fundacja Klaster Lifescience Kraków | |
| Dec 3, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $303$303 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 14, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $0$0 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $931,172.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-01-01 | eCRF+ML diCELLa clinical trials - electronic patient record supported by machine learning algorithms | $329.9K$329,862 | Operational Programme Smart Growth | |
| 2020-09-01 | qCELLa – conducting research and development work on the analysis of medical images using quantum computers. | $482.3K$482,297 | Regional Operational Programme for the Małopolskie Voivodeship for 2014-2020 | |
| 2020-01-07 | diCELLa R&D: Construction of a research and development centre enabling the development of innovative products based on artificial intelligence | $47,564$47,564 | Regional Operational Programme for the Małopolskie Voivodeship for 2014-2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Infomed Software sp. z o.o. | $460,781.60 | infomed-software.pl | ||
| Egabinet sp. z o.o. | $361,329.99 | egabinet.pl | ||
| Lifelogic sp. z o.o. | $330,900.18 | lifelogic.one | ||
| Medchart sp. z o.o. | $326,843.22 | medchart.pl | ||
| LAB - Bit Software S.A. | $329,522.75 | lab-bit.com.pl | ||
| Pergamonmed sp. z o.o. | $296,205.09 | pergamonmed.pl | ||
| Medsi sp. z o.o. | $282,594.01 | medsi.pl | ||
| Notbug sp. z o.o. | $260,918.62 | notbug.pl | ||
| Diagu sp. z o.o. | $220,756.70 | diagu.pl | ||
| Eprzychodnia sp. z o.o. | $149,955.97 | all4medics.online |
Change history
| Date | Event | |
|---|---|---|
| 2025-06-05 | Share capital increase (6,400.00 PLN → 121,600.00 PLN) | |
| 2025-06-05 | Switch to PKD 2025 (3 PKD 2007 codes → 3 PKD 2025 codes) | |
| 2021-06-21 | Address change (Ul. Rakowicka 5/5, 31-511, Kraków → Ul. Podole 60, 30-394, Kraków) | |
| 2019-09-20 | Address change (Ul. Helclów 23/20, 31-148, Kraków → Ul. Rakowicka 5/5, 31-511, Kraków) | |
| 2019-07-04 | Share capital reduction (7,300.00 PLN → 6,400.00 PLN) |
FAQ
Last updated: 2026-07-22